Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Double attack on lymphoma: CAR-T cells followed by antibodies show promise

NCT ID NCT04889716

First seen Mar 21, 2026 · Last updated May 25, 2026 · Updated 8 times

Summary

This study tests whether giving an extra antibody drug (mosunetuzumab or glofitamab) after CAR-T cell therapy can improve results for people with aggressive large B-cell lymphoma that has come back or not responded to prior treatments. About 42 participants will receive the combination and be monitored for safety and how well the cancer responds. The goal is to see if this dual-targeting approach leads to more complete remissions without serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Abramson Cancer Center of the University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Nebraska Medical Center

    RECRUITING

    Omaha, Nebraska, 68198, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.